Biotechnology News and Research

RSS

Histostem awarded U.S. patent for isolation of mesenchymal stem cells

Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.

13 Oct 2009

Biotech Showcase inks pact with Astia to help women-led biotech companies

EBD Group and Demy-Colton Life Science Advisors, the producers of Biotech Showcase™, and Astia today announced a strategic collaboration designed to ensure that women-led biotech companies gain the investor and industry relationships needed to successfully grow their businesses.

12 Oct 2009

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

ImaginAb, Inc. and BZL Biologics, LLC have concluded a sublicense of BZL's PSMA/huJ591 antibody technology for the field of diagnostic imaging for PET and SPECT. "ImaginAb is pleased to have completed this [sub]licensing agreement with BZL as we believe that huJ591 will form the basis of an excellent clinical product for the diagnosis and management of prostate cancer.

12 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR Biosciences Holdings, Inc. (OTCBB: IRBS), today announced that its lead anti-influenza drug, Homspera, will be tested for efficacy against highly lethal H5N1 Avian Influenza in the laboratories of a widely respected University scientist. Additionally, testing at an independent facility will further define the adjuvant efficacy of Homspera when coupled with a novel vaccine for H5N1 in studies sponsored by an ImmuneRegen industry partner.

12 Oct 2009

Santarus and Norgine enter into a licensing agreement for ZEGERID products

Santarus, Inc., a specialty biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, today announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID® products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe.

12 Oct 2009

The third “Exciting Biologies” meeting focuses on “Biology In Balance”

In a continuing series called “Exciting Biologies” Cell Press, Massachusetts General Hospital and La Fondation Ipsen collaborate to offer annual meetings designed to highlight emerging intersections in biomedical research and promote interactions between scientists from converging disciplines. This third meeting, held in Buenos Aires between the 8th and 10th of October, focused on “Biology in Balance”.

12 Oct 2009

BIO disagrees with recommendations of the draft report on Gene Patenting and Licensing

The Biotechnology Industry Organization (BIO) provided comments yesterday to the Secretary’s Advisory Committee on Genetics, Health and Society regarding its draft report on Gene Patenting and Licensing and Their Impact on Patient Access to Genetic Tests. The report makes several recommendations that would restrict the ability to obtain or undermine the enforceability of patents and exclusive licenses with respect to genetic tests.

12 Oct 2009

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, today announced successful completion of the first phase I trial with its anti-inflammatory Spiegelmer® NOX-E36. This drug candidate will be developed for the treatment of complications of type 2 diabetes, preferentially diabetic nephropathy, but also others.

12 Oct 2009

New journal focuses on therapeutic hypothermia and its applications in cardiology and neurotrauma

Therapeutic Hypothermia, a new online open access peer-reviewed journal, will focus on medical treatment which lowers a patient's body temperature to help reduce the risk of ischemic injury to tissues following a period of insufficient blood flow.

12 Oct 2009

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Fibrocell Science, Inc. announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults.

12 Oct 2009

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Selexis SA and Irvine Scientific Inc. announced today plans to jointly present results of a recent collaborative effort combining the Selexis SURE Cell Line Development Programs(TM) and the Irvine IS CHO Culture System, demonstrating the rapid production of gram quantities of monoclonal antibodies from stable CHO production cell lines.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

Locus Pharmaceuticals enters into discovery research collaboration with Novartis

Locus Pharmaceuticals announced today that it has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

12 Oct 2009

Presentations on efficacy of interferon to combat influenza

Amarillo Biosciences, Inc. (ABI) today announced that Professor Dr. Otto Haller from the Department of Virology, Freiburg University, Germany and Professor Dr. Oliver Planz from the Friedrich Loeffler Institute, Tubingen, Germany gave two separate presentations on the efficacy of interferon to combat influenza.

12 Oct 2009

Mediacorp Canada selects MDS Nordion as one of Canada's Top 100 Employers for 2010

MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, has been selected as one of Canada's Top 100 Employers for 2010 by Mediacorp Canada, the nation's largest publisher of employment-related periodicals and online directories.

9 Oct 2009

Czura Thornton to buy MDS' Central Labs operation

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed an agreement to sell its Central Labs operation, which conducts analysis of samples from late-stage clinical trials to Czura Thornton, a private investment group based in Jersey, Channel Islands.

From Danaher 9 Oct 2009

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has been awarded a proof of concept contract by the U.S. Army Research, Development and Engineering Command laboratory specifically the Edgewood Chemical Biological Center ("ECBC") Research & Technology Directorate.

9 Oct 2009

Czura Thornton to acquire MDS's Central Labs operation

From Danaher 9 Oct 2009

International symposium examines how new advances in plant science research can benefit African agriculture

This three-day international symposium is designed to bring together scientists from Africa, Europe and the USA to examine how new advances in plant science research and developing technologies can be used to the benefit of African agriculture

9 Oct 2009

Biotechnology News and Research

Histostem awarded U.S. patent for isolation of mesenchymal stem cells

Biotech Showcase inks pact with Astia to help women-led biotech companies

ImaginAb and BZL Biologics conclude sublicense agreement for antibody technology

QRxPharma signs contractual agreement with Patheon

ImmuneRegen BioSciences to test efficacy of Homspera against H5N1 Avian Influenza

Santarus and Norgine enter into a licensing agreement for ZEGERID products

The third “Exciting Biologies” meeting focuses on “Biology In Balance”

BIO disagrees with recommendations of the draft report on Gene Patenting and Licensing

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

New journal focuses on therapeutic hypothermia and its applications in cardiology and neurotrauma

FDA advisory committee reviews Fibrocell Science's azfibrocel-T for treating wrinkles

Selexis and Irvine Scientificti to jointly present results of recent collaborative effort

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Locus Pharmaceuticals enters into discovery research collaboration with Novartis

Presentations on efficacy of interferon to combat influenza

Mediacorp Canada selects MDS Nordion as one of Canada's Top 100 Employers for 2010

Czura Thornton to buy MDS' Central Labs operation

Medicago receives contract from U.S. Army Research, Development and Engineering Command laboratory

Czura Thornton to acquire MDS's Central Labs operation

International symposium examines how new advances in plant science research can benefit African agriculture

Biotechnology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News